For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
TB-500
Regenerative Peptide
Dosage
Quantity
Price
$34.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- TB-500 10mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
TB-500 refers to a fragment of thymosin β4 (Tβ4). Human Phase 1 safety exists, but most mechanistic and wound data are preclinical. Not FDA approved for any indication.
Research status
Where Tβ4 / TB-500 sits
- Origin
- Endogenous peptide — thymus, platelets, wound fluid
- Discovery era
- Thymosin research lineage (1960s onward)
- Clinical programs
- Dry eye Phase 2 completed; cardiac Phase 1 explored
- Regulatory framing
- Investigational — not Rx-grade for general use
Cross-check active arms on ClinicalTrials.gov.
170+
Indexed literature
Review-level citations (e.g. Goldstein et al. frameworks) underpin many education summaries.
61%
Re-epithelialization
Faster resurfacing vs controls at day 7 in rat full-thickness wound models.
0
Serious adverse events
Phase 1 IV cohorts (42–1260 mg) × 14 days reported no serious events in primary safety narratives.
43
Amino acids
Synthetic fragment aligned with the parent Tβ4 sequence domain.
0.95–1.9h
Half-life (IV)
Dose-dependent terminal phase in the same Phase 1 pharmacokinetic summaries.
Human safety
Phase 1 tolerability
Randomized, placebo-controlled exposure in healthy volunteers (Ruff et al., 2010) established wide IV dose escalation without dose-limiting toxicity in the published account.
- Serious adverse eventsNone reported
- Dose-limiting toxicityNone identified
- Completion (AE-related dropout)100% finished protocol
Ann N Y Acad Sci — Phase 1 compilation.
Wound biology (preclinical)
Saline-controlled rat models
Fold-change metrics exceed 100% bar scale—see original plots.
J Invest Dermatol (1999).
Stroke model dose ladder
Ceiling effect narrative
Higher exposure can erase benefit—always map to the exact species model before extrapolating.
Program metrics
Trial design anchors
- Optimal stroke-model dose (cited): 3.75 mg/kg
- Phase 1 dosing window: 14-day multidose IV schema
- Efficacy caveat: wound data remain chiefly preclinical
FDA approval has not been granted; sponsor trials continue to evolve.
Inflammation biology
NF-κB & innate receptor tone
Tβ4 is described as dampening NF-κB and toll-like receptor–driven damage while engaging repair kinases during remodeling windows.
- NF-κB signaling
- Modulated ↓
- Inflammatory cytokines
- Reduced ↓
- PI3K / Akt / eNOS
- Activated ↑
- Notch pathway
- Regulated ↑
Phase 2 complete
Ocular surface
Tβ4 ophthalmic solution advanced for dry eye with published safety/efficacy discussion.
Stroke / TBI models
Neuro recovery
Oligodendrogenesis, myelination, and functional gains reported between days 14–56.
ILK axis
Cardiac repair
Integrin-linked kinase activation, migration, and survival signaling (Nature, 2004).
Dermal models
Wound closure
61% faster resurfacing at day 7 vs saline in classic rat excision data.
Cardiac repair depth
ILK-linked survival programs
Preclinical myocardial injury models tie Tβ4 to integrin-linked kinase activation and improved cardiomyocyte migration/survival.
Nature (2004).
Neurological recovery
Stroke & TBI models
Literature highlights oligodendrocyte lineage expansion, myelination, and functional gains between 2 and 8 weeks.
- Oligodendrocyte progenitors ↑ in SVZ niches
- Mature oligodendrocytes ↑ in corpus callosum
- Striatal myelination enhancements
- Behavioral recovery windows: days 14–56
J Neurol Sci (2014).
Complementary stack context
TB-500 is frequently contrasted with BPC-157 because motility/actin biology differs from VEGFR2-weighted angiogenesis stories—overlap often cited in anti-inflammatory phenotypes.
- TB-500 emphasis
- Actin filament / cell migration
- BPC-157 emphasis
- VEGFR2 / angiogenesis
Safety profile from research
Phase 1 human + long preclinical tail; long-term human surveillance thin.
Common mild events
Headache
MildUpper respiratory
MildInjection site
MildTheoretical migration / angiogenesis
Pro-migratory biology invites tumor hypotheticals; some models actually hint at anti-metastatic behavior—none of this replaces oncology diligence.
Phase 1 safety table
- Serious adverse events: 0 across 42–1260 mg IV arms (reported)
- Dose-limiting toxicities: none identified
- Discontinuations for AE: none cited
- Emergent events: mild/moderate intensity only
Regulatory reality
- FDA: unapproved drug when marketed for human use
- WADA: prohibited (S0)
- Not a mainstream prescription product
- Pregnancy / lactation data essentially absent
Storage handling reference
Peptide handling
Cold
Lyophilized: −20°C or colder.
Sterile
Use aseptic reconstitution.
Light
Limit exposure during aliquoting.
Aliquot
Avoid repeat freeze-thaw.
Researcher notes
- Forty healthy volunteers in the landmark Phase 1 narrative showed excellent short-term tolerability.
- Rodent and canine tox packages report NOEL ≥18 mg/kg with higher dog doses producing benign salivation—clinical relevance unclear.
- Always reconcile vial content with published human-equivalent dosing; mg/kg animal numbers do not translate linearly.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.